Founded in 1970, Hengrui Medicine is an international pharmaceutical company engaged in the development and promotion of innovative and high-quality drugs. It focuses on the research and development of new drugs in the fields of anti-tumor, surgical drugs, autoimmune diseases, metabolic diseases, cardiovascular diseases and other fields.

For many years, Hengrui Medicine has always been rooted in China and facing the world, focusing on health, focusing on cutting-edge fields, and overcoming difficulties to promote high-quality development of the pharmaceutical industry. The company regards scientific and technological innovation as its first development strategy and continues to invest in R&D with high intensity. The company has invested a total of 23.8 billion yuan in R&D in the past decade, of which 6.203 billion yuan of R&D investment in 2021, and the proportion of R&D investment in operating income reached 23.95%, ranking The forefront of the industry. The company has successively established R&D centers or branches in Lianyungang, Shanghai, Chengdu, the United States and Europe, and has built a global R&D team with a scale, professional and comprehensive capabilities of more than 5,000 people. At present, the company has 12 innovative drugs including reverutamide, hitrapopal, carrilizumab, etc., and the first new drug introduced by the company has also been approved for marketing. This is also the company's external cooperation. Among the products, more than 60 innovative drugs are being clinically developed, and more than 260 clinical trials are being carried out at home and abroad. The company has rich R&D pipelines. In addition to the traditional advantageous tumor field, it also prospectively and widely deploys multiple therapeutic areas such as autoimmune diseases, pain management, cardiovascular diseases, and metabolic diseases. The company has also established a number of new technology platforms with independent intellectual property rights and internationally advanced to provide strong basic guarantees for innovation and research and development. As of the end of 2022, the company has applied for 2,064 invention patents, 583 PCT patents, 507 valid domestic invention patents, and 618 authorized patents from Europe, America, Japan and other countries.

The company continues to steadily promote internationalization. As of the end of 2021, Hengrui Pharmaceutical products have entered more than 40 countries, and are continuing to accelerate the development of global markets and focus on emerging markets. The company insists on both independent research and development and open cooperation, and strengthens international cooperation on the basis of endogenous development. Through cooperation with American and Korean companies, the company authorizes innovative drugs with independent intellectual property rights such as SHR2554, carrilizumab, SHR0302 to the public. In addition, Hengrui Medicine has obtained more than 20 registration approvals including injections, oral preparations and inhaled anesthetics in Europe, the United States and Japan, improving the accessibility of drugs in patients in different regions around the world.

Perseverance leads to a long-term future, and a prosperous life. In the future development, Hengrui will continue to adhere to the mission of "technology-based, creating a healthy life for mankind", with the vision of "focusing on innovation and building a multinational pharmaceutical group", accelerate technological innovation, and strive to develop more new drugs, Good medicines benefit patients and better serve healthy life!